Introduction
Reducing the early morning blood pressure surge (EMBPS) is an emerging objective of antihypertensive therapy. [1] [2] [3] The peak incidence of atherosclerotic plaque rupture and acute cardiovascular events occurs in the morning, at the same time as surges in BP, pulse rate, sympathetic tone and the activity of the renin-angiotensin-aldosterone system. [4] [5] [6] [7] Recent prospective studies using ambulatory BP monitoring (ABPM) are beginning to elucidate the pathogenic significance of the EMBPS, notably as a risk factor for ischaemic stroke. [8] [9] [10] The clinical application of antihypertensive therapy, however, has not kept pace with the progress in circadian biology. 11 In a recent editorial, Kario 1 has described morning hypertension as the 'blind spot' of current management. A key consideration is that antihypertensive medication is taken once daily, shortly after the patient wakes in the morning. [12] [13] [14] After a given day's dose, the next EMBPS occurs towards the end of the dosing cycle, as treatment efficacy approaches its nadir.
Telmisartan, an angiotensin II receptor blocker (ARB) with a plasma half-life (t1 2 ) of B24 h, provides sustained BP control throughout the daily dosing cycle. 15, 16 Ramipril (t1 2 , 13-17 h), a widely used angiotensin-converting enzyme (ACE) inhibitor, is of proven efficacy in the prevention of cardiovascular events. 17 We have pooled the data from two clinical trials comparing the antihypertensive efficacy of telmisartan and ramipril at the end of the 24-h dosing cycle (that is, in the early-morning period). This pooled analysis provides the largestever study of an ACE inhibitor vs an ARB with regard to 24-h BP control and the EMBPS.
Methods

Study design
This was a prospectively designed analysis of two studies; Prospective, Randomized Investigation of the Safety and Efficacy of Micardis vs Ramipril Using ABPM (PRISMA) I 18 and PRISMA II (no. 502.392 and no. 502.391, respectively). 19 These were prospective, randomized, open-label, blinded end point (PROBE) clinical trials that evaluated BP control during the final 6 h of the 24-h dosing cycle in patients randomized to a forced-titration treatment with either telmisartan or ramipril. PRISMA I and II were conducted in 10 countries, namely Austria, Canada, France, Germany, The Netherlands, South Africa, Spain, Switzerland, the United Kingdom and the United States.
Adults (X18 years) were potentially eligible for treatment randomization if they had mild or moderate (stage I or II) primary hypertension, with both a mean clinic-seated systolic BP (SBP)/diastolic BP (DBP) of o180/95-109 mm Hg at enrolment and a mean 24-h DBP 485 mm Hg at baseline. For premenopausal women, adequate contraception was an additional inclusion criterion. The principal healthrelated exclusion criteria were a confirmed or suspected history of coronary artery disease, congestive heart failure or a recent acute cardiovascular event (such as stroke within 6 months or myocardial infarction within 3 months), poorly controlled insulin-dependent diabetes mellitus and chronic kidney disease. Employment as a night shift worker was an additional exclusion criterion.
Study conduct
Study procedures were approved by the institutional review boards/clinical trial ethics committees of the participating centres. All patients gave written informed consent.
Hypertensive status was confirmed at the end of a 2-to 4-week placebo run-in period. At baseline, patients were randomized, in a 1:1 ratio, to 14 weeks' once-daily, open-label monotherapy with either telmisartan (MICARDIS À , Boehringer Ingelheim GmbH, Ingelheim, Germany) or ramipril (Altace, Aventis Pharma Inc., Laval, QC, Canada). Dosing in each treatment arm adhered to a forcedtitration regimen (Figure 1 ), whereby the respective doses at initiation (baseline), after 2 weeks and after 8 weeks were telmisartan 40/80/80 mg and ramipril 2.5/5/10 mg. Study medication was administered each day at 0900 ± 1300 hours.
Efficacy evaluations were conducted after 8 and 14 weeks. At each evaluation, a 90207 ambulatory BP monitor (SpaceLabs Medical Data, Redmond, WA, USA) was attached to the participant's nondominant arm, and monitoring commenced immediately after the scheduled administration of the study medication. Measurements were taken at 20-min intervals throughout each monitoring period. Evaluability of individual measurements and of complete ABPMs was assessed using pre-specified screening rules. Mean values were calculated for each hour relative to the time of dosing. Triplicate measurements of trough-seated BP were taken with an office cuff sphygmomanometer, in accordance with the guidelines of the American Society of Hypertension. 20 The primary end point was the change, from baseline to evaluation, in the mean ambulatory BP during the final 6 h of the 24-h dosing schedule. Secondary end points included changes from baseline in the mean ambulatory BP during the 24-h dosing interval, the morning (0600 to 1159 hours), daytime (0600 to 2159 hours) and night time (2200 to 0559 hours); and in the 24-h BP load. An ambulatory SBP treatment response was defined as a mean 24-h SBP o130 mm Hg and/or a reduction from the mean baseline SBP X10 mm Hg, whereas ambulatory SBP control was defined as a mean 24-h SBP p130 mm Hg. An ambulatory DBP treatment response was defined as a mean 24-h DBP o80 mm Hg and/or a reduction from the mean baseline DBP X10 mm Hg, whereas ambulatory DBP control was defined as a mean 24-h DBP o80 mm Hg. Trough clinic-seated BP end points included SBP treatment response (SBP of o140 mm Hg and/or a reduction from baseline of X10 mm Hg), DBP response (DBP o90 mm Hg and/ or a reduction from baseline of X10 mm Hg) and DBP control (DBP o90 mm Hg).
The safety evaluation, which included all patients who received at least one dose of study medication, involved monitoring of the frequency and intensity of all adverse events, of those classified as serious or drug-related and of those prompting study Telmisartan vs ramipril: pooled PRISMA I and II B Williams et al discontinuation. Pulse rate was monitored and recorded while the patient was ambulatory, as well as between the second and third trough-seated BP measurements.
Statistical analyses
Analysis of the primary and all secondary end points was based on the intention-to-treat principle, and included data for all participants who received at least one dose of study medication and for whom valid baseline and follow-up ambulatory or manual in-clinic BP measurements were available. Treatment effects were compared using analysis of covariance, adjusting for study, treatment-by-study interaction and baseline. Response rates were evaluated using the Cochran-Mantel-Haenszel statistics, adjusting for study. A two-sided significance level (P) of 0.05 was assumed.
Results
Subjects
A total of 3591 patients were enrolled, but 1978 were not randomized, mainly because they did not meet the ABPM inclusion criteria. At baseline, the pooled study population comprised 1613 patients, of whom 802 were randomized to telmisartan and 811 to ramipril. At completion of the study, 1436 (89.0%) participants remained, comprising 716 (89.3%) in the telmisartan and 720 (88.8%) in the ramipril arm. Adverse events (telmisartan, 28; ramipril, 44) were the most frequent reason for study discontinuation. Less frequent reasons included lack of treatment efficacy (telmisartan, 12; ramipril, 10) and withdrawal of consent (telmisartan, 18; ramipril, 10).
The demographic profiles of the two treatment groups were closely matched (Table 1) . In both groups, B63% of patients were male and the mean age was B53 years; overall, most (B86%) participants were younger than 65 years. Body mass index, ethnic origin and BP profile were similarly well matched between treatment groups, with a 24-h mean baseline ambulatory BP of B148/93 mm Hg in both groups and comparable measurements for both the mean last 6-h ambulatory BP and the mean trough clinic-seated BP at baseline. The mean duration of diagnosed hypertension was B6 years and B74% of the patients had been diagnosed as hypertensive for more than 1 year.
Primary end point
Once-daily telmisartan of 80 mg was significantly superior to once-daily ramipril of 5 or 10 mg during the last 6 h of the 24-h dosing period (Figure 2) , which is consistent with its sustained duration of effect and pharmacokinetic profile. After 8 weeks (Figure 2a) , the reductions in SBP and DBP were greater with telmisartan of 80 mg than with ramipril of 5 mg, by À5.8 mm Hg (95% confidence interval (CI): À6.9, À4.7; Po0.0001) for SBP and by À4.2 mm Hg (95% CI: À5.0, -3.5; Po0.0001) for DBP. After 14 weeks (Figure 2b ), the corresponding reductions in SBP and DBP were greater with telmisartan of 80 mg than with ramipril of 10 mg, by -4.1 mm Hg (95% CI: À5.2, À2.9; Po0.0001) for SBP and by -3.0 mm Hg (95% CI: À3.8, À2.2; Po0.0001) for DBP. Overall, the efficacy advantage with telmisartan was consistent across the PRISMA I and II studies, with no evidence of either a study effect or a study-by-treatment interaction; therefore, pooling of the data was appropriate.
Secondary end points
Telmisartan of 80 mg reduced the mean 24-h, morning, daytime and night-time ambulatory SBP and DBP, as well as the mean 24-h BP load, to a greater extent than did ramipril, at both efficacy evaluations (Po0.0001 for all comparisons; Table 2 , Figures 3 and 4) . Similarly, the rates of ambulatory SBP and DBP treatment response and DBP control were greater with telmisartan of 80 mg than with ramipril, at both evaluations (Po0.0001 for comparisons) (Table 3) .
Changes in trough-seated BP were broadly consistent with those in ambulatory BP. After 8 weeks, the adjusted mean difference in reduction of SBP Telmisartan also provided superior response rates and control of trough-seated BP (Table 4) .
Tolerability and safety
Both antihypertensive agents were well tolerated, and the overall incidence of adverse events in the two treatment arms was low. The number of patients reporting one or more adverse events, typically of mild or moderate intensity, was 323 (40.3%) with telmisartan and 364 (44.9%) patients with ramipril. The only significant difference in adverse events between the two groups was in the incidence of cough, which affected 11 (1.4%) patients in the telmisartan group, as opposed to 68 (8.4%) patients in the ramipril group (Po0.0001, Fisher's exact test). Telmisartan was also associated with a lower incidence of adverse events that was considered by the investigators to be related to treatment (7.4%) than was ramipril (11.6%) (P ¼ 0.0038). This was primarily because of the lower incidence of treatment-related cough (0.4 vs 6.9%).
By medication and dose, the numbers of patients who reported severe adverse events were telmisartan of 40 mg, 4 (0.5%); telmisartan of 80 mg, 24 (3.1%); ramipril of 2.5 mg, 15 (1.8%); ramipril of 5 mg, 18 (2.3%); and ramipril of 10 mg, 14 (1.9%) patients. Serious adverse events were experienced by 8 telmisartan-treated and 11 ramipril-treated Telmisartan vs ramipril: pooled PRISMA I and II B Williams et al patients, and none was classed by the investigators as treatment-related. In the course of the study, no patient died and there were no clinically significant changes in vital signs.
Discussion
The pooled PRISMA I and II ambulatory BP database is among the largest ever compiled from clinical trials prospectively comparing an ARB with an ACE inhibitor. Analysis of this database has shown that once-daily telmisartan of 80 mg was significantly superior to once-daily ramipril of 5 or 10 mg in the last 6 h of the 24-h dosing interval. Although at the 8-week time point the ramipril dose of 5 mg once daily might be considered sub-optimal when compared with the telmisartan dose of 80 mg once daily, the significant differences in BP control persisted in the last 6 h of the 24-h dosing interval, even after the ramipril dose had been force-titrated to 1 mg once daily from the 8th to the 14th week of the study. The superiority of telmisartan over ramipril in this time period is consistent with the established pharmacokinetic profiles of these agents. [21] [22] [23] It is also consistent with the results of other trials using 24-h ABPM that have shown superior efficacy of telmisartan compared with antihypertensives from a range of classes, including losartan, 24, 25 valsartan, 15 ,16 amlodipine 26 and perindopril. 27 Evidence that reduction of morning BP provides clinical benefit comes from a study of patients with type II diabetes, hypertension and nephropathy, in whom a reduction of morning SBP in response to antihypertensive treatment was shown to correlate significantly with a slowing of the progression of renal damage. 28 In the analysis reported here, telmisartan produced reductions in BP in the last 6 h of the dosing interval that were greater than those produced by ramipril of 10 mg by À4.1 mm Hg for SBP and À3.0 mm Hg for DBP, a difference that is large and more likely to be clinically meaningful.
Control of morning BP is often poor, even in patients with controlled office BP. In the analysis of the control of BP using ABPM (ACAMPA study), 62% of patients with controlled office BP were found to have ambulatory morning BP 4138/ 85 mm Hg. 29 In the Jichi Morning Hypertension Research (J-MORE) study, which used home BP monitoring, the equivalent figure was 61%. 8 This study shows that more widespread use of longeracting agents could improve these figures.
The treatment difference favouring telmisartan was not confined to the last quarter of the daily dosing schedule, but was evident in each hour during 24-h ABPM, as well as in the mean 24-h measurements. The clinical relevance of this result is suggested by the fact that 24-h ABPM gives a high degree of correlation with the risk of cardiovascular disease (superior, indeed, to that obtained with office BP measurements). 30 The difference between telmisartan and ramipril in mean 24-h SBP, amounting to À3.1 mm Hg, is clinically significant, given that a À2 mm Hg reduction in SBP has been shown to be associated with a reduction in mortality of 7% for ischaemic heart disease and 10% for stroke. 31 The recent large outcome study, the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), investigated the cardiovascular protective benefits of telmisartan and ramipril in a broad range of highcardiovascular-risk patients. 32 In the ONTARGET study, telmisartan was non-inferior to ramipril in preventing a composite of cardiovascular events that formed the primary end point, that is a composite of death from cardiovascular causes, myocardial infarction, stroke and hospitalization for heart failure. Mindful of the fact that our study shows that telmisartan is more effective than ramipril at controlling BP, the result of ONTARGET might seem surprising. However, it is important to recognize that the ONTARGET study was not a study of hypertension treatment. Approximately 30% of patients were considered normotensive at randomization and the remaining patients had their BP treated with a variety of concomitant medications and these increased as the study progressed. The average BP of the ONTARGET population at randomization was B142/ 82 mm Hg. This is important because the ability to show differences in BP-lowering efficacy between treatments diminishes at a lower baseline BP and is further diminished by the addition of concomitant medications. Thus, the smaller difference in BP between the ramipril vs telmisartan arms of the ONTARGET study (difference 0.9/0.6 mm Hg in favour of telmisartan) can be accounted for by the design of the ONTARGET study, which was not focused on showing differences in BP-lowering efficacy between treatment arms. Ongoing analyses of the ABPM substudy of the ONTARGET study patients will provide more data in this area.
The ambulatory BP response rates to telmisartan in the PRISMA studies were high, with a DBP response in 450% of patients and an SBP response in B70% of patients, which is consistent with earlier studies. 33 Control of trough DBP was achieved in 54.2% of patients treated with telmisartan of 80 mg, as opposed to only 40.4% with ramipril of 10 mg, a potentially important finding given that office BP currently remains uncontrolled in more than half of treated hypertensive patients in Europe and the United States. 34 Although the PRISMA studies used a PROBE design, rather than the more accepted double-blind design, this is not a major limitation. The PROBE design was used because it closely reflects clinical practice, whereas the end point assessment is clearly independent from knowledge of the patients' treatment allocation. Furthermore, PROBE studies have been shown earlier to provide results equivalent to those achieved by double-blind studies, 35 and are also acceptable for use with ABPM. As discussed above, an additional potential limitation of the study design could be that the ramipril dose used in the present studies is submaximal (that is, at a minimum in the United States); however, the doses of drugs selected for initial and maximal therapy were those typically used in clinical practice to treat hypertension. The PRISMA studies were conducted in both Europe (PRISMA I) and North America (PRISMA II). Telmisartan of 80 mg was chosen because it is the maximum approved dose in both Europe and the United States. The maximum approved dose of ramipril varies in Europe (10 mg) and the United States (20 mg). For consistency, ramipril of 10 mg was used in both PRISMA studies, and the patients were force-titrated to this dose for 6 weeks before the final efficacy comparison. Moreover, this dose of ramipril has shown earlier BPlowering efficacy and cardiovascular protection. 17, 36 In conclusion, pooled analysis of PRISMA I and II shows that the antihypertensive efficacy of once-daily telmisartan of 80 mg was consistently superior to that of once-daily ramipril of 5 or 10 mg. Although the treatment difference favouring telmisartan was maintained throughout the 24-h dosing cycle, it was especially marked during the last 6 h, when the EMBPS is typically associated with a peak in cardiovascular risk. This reflects the longer duration of action of the ARB. Moreover, the superior efficacy of telmisartan over ramipril was comprehensively shown, across the range of pre-specified end points, with treatment differences persisting despite the forced titration of the ramipril dose, from 5 to 10 mg, between evaluations. The findings of our study are important because they suggest that the better quality of 24-h BP control and improved tolerability of the ARB could ultimately turn out to be the most important difference between ARBs and ACE inhibition.
